Aclaris Therapeutics (ACRS) Cash & Equivalents (2014 - 2026)

Aclaris Therapeutics' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $28.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 5.59% year-over-year to $28.7 million; the TTM figure through Mar 2026 stood at $28.7 million (down 5.59% YoY), while the FY2025 annual figure was $20.0 million, down 18.76% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $28.7 million, up from $20.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $68.3 million in Q2 2022, with the low at $20.0 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $35.8 million (2024), against an average of $36.9 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 65.55% in 2022, then tumbled 54.37% in 2023.
• Aclaris Therapeutics' Cash & Equivalents stood at $45.3 million in 2022, then decreased by 11.92% to $39.9 million in 2023, then tumbled by 38.39% to $24.6 million in 2024, then dropped by 18.76% to $20.0 million in 2025, then soared by 43.59% to $28.7 million in 2026.
• Business Quant data shows ACRS's Cash & Equivalents at $28.7 million in Q1 2026, $20.0 million in Q4 2025, and $25.3 million in Q3 2025.